ADGI
NASDAQAdagio Therapeutics Inc.
Adagio Therapeutics Inc. (ADGI) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for ADGI in the last 30 days. The most recent was published Feb 28, 2023.
Latest news
25 items- PRInvivyd to Participate at Cowen's 43rd Annual Healthcare ConferenceWALTHAM, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced David Hering, chief executive officer of Invivyd, is scheduled to present at Cowen's 43rd Annual Healthcare Conference on Monday, March 6, 2023 at 2:10 p.m. ET. A live webcast of the presentation will be available in the investor section of the company's website at investors.invivyd.com and will be archived for 90 days following the presentation. About Invivyd(NASDAQ:IVVD)Invivyd, Inc., formerly Adagio Therapeutics (NASDAQ:ADGI), is a biopharmaceutical company on a mission to prot
- PRInvivyd Announces Changes to Executive TeamWALTHAM, Mass., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a clinical stage biopharmaceutical company on a mission to protect humanity from serious infectious diseases, today announced that Laura Walker, Ph.D., the company's chief scientific officer and co-founder, decided to leave the company to pursue other opportunities. The management team has initiated a search process to identify her replacement. Until a permanent successor is named, Invivyd team member Lukas Dillinger, Ph.D., has been appointed as interim Head of Discovery and Pre-Clinical. "On behalf of the company, I extend my gratitude and thanks for Laura's scientific passion and contributions that led to
- SECAdagio Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Invivyd, Inc. (0001832038) (Filer)
- PRInvivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA WorkshopWALTHAM, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, was invited to participate in an FDA-EMA workshop on SARS-CoV-2 monoclonal antibodies held on December 15, 2022. Invivyd's chief scientific officer, Laura Walker, Ph.D., alongside Eli Lilly and Company and Regeneron Pharmaceuticals, Inc., presented a joint industry approach for anti-spike monoclonal antibody development to keep pace with SARS-CoV-2 variants. The meeting featured presentations by scientists, clinicians, regulators, and industry representatives to discuss alternative strategies to s
- INSIDERSEC Form 4 filed by Dabora Rebecca4 - Invivyd, Inc. (0001832038) (Issuer)
- INSIDERSEC Form 4 filed by Andersen Jill4 - Invivyd, Inc. (0001832038) (Issuer)
- INSIDERSEC Form 4 filed by Schmidt Peter4 - Invivyd, Inc. (0001832038) (Issuer)
- INSIDERSEC Form 4 filed by Gowler Jeremy4 - Invivyd, Inc. (0001832038) (Issuer)
- INSIDERSEC Form 3 filed by new insider Gowler Jeremy3 - Invivyd, Inc. (0001832038) (Issuer)
- INSIDERSEC Form 4 filed by Hering David4 - Invivyd, Inc. (0001832038) (Issuer)
- INSIDERSEC Form 4 filed by Schmidt Peter4 - Invivyd, Inc. (0001832038) (Issuer)
- INSIDERSEC Form 3: New insider Schmidt Peter claimed ownership of 6,971 shares3 - Invivyd, Inc. (0001832038) (Issuer)
- SECAdagio Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits8-K - Invivyd, Inc. (0001832038) (Filer)
- PRInvivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical OfficerWALTHAM, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the appointment of Jeremy Gowler as chief operating and commercial officer, effective December 16, 2022, and the promotion of Pete Schmidt, M.D. to chief medical officer, effective immediately. In his new role Mr. Gowler will oversee operations and commercial activities for the company. Dr. Schmidt will be responsible for overseeing all medical, clinical development and regulatory activities at Invivyd. Dr. Ellie Hershberger, Invivyd's chief development officer, is departing f
- SECSEC Form D filed by Adagio Therapeutics Inc.D - Invivyd, Inc. (0001832038) (Filer)
- SECAdagio Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Invivyd, Inc. (0001832038) (Filer)
- PRInvivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19-Broad partnership will strengthen Invivyd's development platform and organizational capabilities towards acceleration of NVD200 clinical program and future engineered antibodies for COVID-19 and beyond- -Population Health Partners to integrate best-in-class capabilities to drive speed and efficiency in clinical development, demonstrated by the success of PHP's leadership team at The Medicines Company, Pfizer and elsewhere in the life sciences industry- WALTHAM, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced a partnership with Populat
- SECSEC Form 10-Q filed by Adagio Therapeutics Inc.10-Q - Invivyd, Inc. (0001832038) (Filer)
- SECAdagio Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Invivyd, Inc. (0001832038) (Filer)
- PRInvivyd Reports Third Quarter 2022 Financial Results and Business HighlightsNovel monoclonal antibody combination candidate (NVD200) on track to advance into clinical trials in Q1 2023 $419 million in cash, cash equivalents and marketable securities expected to support operating runway into Q2 2024 Conference call scheduled for Thursday, November 10th at 4:30 p.m. ET WALTHAM, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced financial results and business highlights for the third quarter ended September 30, 2022. "It has been a productive quarter starting with a corporate rebrand emphasizing our commitment to e
- PRInvivyd to Participate in Fireside Chat at the Jefferies London Healthcare ConferenceWALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced David Hering, chief executive officer of Invivyd, is scheduled to participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 4:25 p.m. GMT. A live webcast of the fireside chat will be available in the investor section of the company's website at investors.invivyd.com and will be archived for 90 days following the presentation. About Invivyd(NASDAQ:IVVD)Invivyd, formerly Adagio Therapeutics (NASDAQ:ADGI), is a biopharmaceutical com
- INSIDERSEC Form 4 filed by Andersen Jill4 - Invivyd, Inc. (0001832038) (Issuer)
- PRInvivyd to Host Conference Call on November 10 to Discuss Third Quarter 2022 Financial Results and Recent Business HighlightsWALTHAM, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced that it will host a conference call on Thursday, November 10, 2022, at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2022, and recent business highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan o
- INSIDERSEC Form 4 filed by Lindenboom Christine4 - Invivyd, Inc. (0001832038) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lindenboom Christine3 - Invivyd, Inc. (0001832038) (Issuer)
ADGI FAQ
8 questionsWhat does Adagio Therapeutics Inc. do?
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. Its lead product candidate is the ADG20, a neutralizing antibody that is in Phase II/III clinical trials for the treatment and prevention of coronavirus disease. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. Adagio Therapeutics, Inc. was incorporated in 2020 and is based in Waltham, Massachusetts.What is the latest news on ADGI?
Quantisnow has not tracked any new filings, ratings or press releases for ADGI in the last 30 days. The most recent wire item was published on February 28, 2023.Where does ADGI stock trade?
Adagio Therapeutics Inc. (ADGI) is listed on NASDAQ.What sector and industry is ADGI in?
Adagio Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Adagio Therapeutics Inc. go public?
Adagio Therapeutics Inc. (ADGI) completed its IPO in 2021.What are analysts saying about ADGI?
Across the last 8 analyst actions on Adagio Therapeutics Inc., there was 1 upgrade and 6 downgrades. The most recent action was from Morgan Stanley: Underweight with a $6.00 price target on 2022-01-06.What companies are similar to ADGI?
Notable peers in the same industry include AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.), ABBV (AbbVie Inc.). Compare ADGI side-by-side with any of them on Quantisnow.How can I track ADGI on Quantisnow?
Quantisnow aggregates Adagio Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ADGI to receive live email and push alerts on every new disclosure.